ProCE Banner Series

Transforming Precision NSCLC Care: Educating and Supporting Patients on HER2- and TROP2-Targeted ADCs

Expert discussions and takeaways for the evolving treatment landscape for HER2- and TROP2-targeted antibody–drug conjugates in NSCLC.

  AAPA
  | ANCC
Who Should Attend

This program is intended for nurse practitioners, physician associates, clinical nurse specialists, and advanced degree nurses who manage patients with NSCLC eligible for treatment with HER2- and TROP2-targeted ADCs.

All Events

Transforming Precision NSCLC Care: Educating and Supporting Patients on HER2- and TROP2-Targeted ADCs

Upcoming Events

October

25

2024

10:30 AM - 12:30 PM Central Time (CT)

Virtual

Faculty

ProCE Banner Faculty
Edward B. Garon, MD, MS

Professor
Director of Thoracic Oncology
David Geffen School of Medicine at UCLA
Co-Director of Signal Transduction and Therapeutics Program
Jonsson Comprehensive Cancer Center at UCLA
Los Angeles, California

ProCE Banner Faculty
Blanca Ledezma, MSN, NP-AOCNP

Nurse Practitioner III
Division of Hematology/Oncology
UCLA Santa Monica
Santa Monica, California

ProCE Banner Faculty
Denise Rouse, MS, PA-C

Physician Assistant
Thoracic Medical Oncology
Department of Medicine, Section of Hematology/Oncology
The University of Chicago Medicine & Biological Sciences
Chicago, Illinois

Topics

Lung Cancers

Additional Info

There are no fees required to participate in this activity.

Americans With Disabilities Act
Event staff will be glad to assist you with any special needs (eg, physical, dietary). Please contact Customer Support prior to the live event.

CME/CE Info

Goal Statement
This program aims to improve learners’ knowledge and competence to optimize the treatment of NSCLC with HER2- and TROP2-targeted ADCs. 

Target Audience
This program is intended for nurse practitioners, physician associates, clinical nurse specialists, and advanced degree nurses who manage patients with NSCLC eligible for treatment with HER2- and TROP2-targeted ADCs. 

Learning Objectives
Upon completion of this activity, participants should be able to:

  • Outline the role of HER2 and TROP-2 in NSCLC prognosis and treatment and key points for patient education in this area
  • Plan individualized treatment strategies for use of approved HER2-targeted ADC therapy in NSCLC, considering current evidence and guidelines, patient factors and preferences, and disease-related factors
  • Review current clinical trial evidence for targeting TROP-2 in patients with NSCLC with and without actionable genomic alterations
  • Assess patients for eligibility to enroll in clinical trials of combination strategies that include TROP2 or HER2-targeted ADCs in NSCLC
  • Apply communication strategies and recommended actions to identify and manage AEs and to increase patient awareness of potential ADC-related toxicities

Accreditation

Joint Accreditation Statement

In support of improving patient care, Partners for Advancing Clinical Education (PACE) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. 

Nursing Continuing Professional Development

The maximum number of hours awarded for this Nursing Continuing Professional Development activity is 2.0 contact hours, including 2.0 hours of pharmacotherapy credit.

Physician Associate Continuing Medical Education

Partners for Advancing Clinical Education (PACE) has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 2.0 AAPA Category 1 CME credits. PAs should only claim credit commensurate with the extent of their participation.

IPCE Credit Designation

This activity was planned by and for the healthcare team, and learners will receive 2.00 Interprofessional Continuing Education (IPCE) credits for learning and change.

Disclosure of Conflicts of Interest
PACE requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. All relevant financial relationships are mitigated according to PACE policies.

Acknowledgement

Provided by Partners for Advancing Clinical Education in partnership with Practicing Clinicians Exchange, LLC and Clinical Care Options, LLC.

Supported by educational grants from AstraZeneca and Daiichi Sankyo, Inc.